Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
270.19
+19.04 (7.58%)
At close: May 12, 2025, 4:00 PM
272.00
+1.81 (0.67%)
After-hours: May 12, 2025, 6:48 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,052,959
Profits / Employee
-$120,942
Market Cap
35.23B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALNY News
- 13 hours ago - Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
- 7 days ago - Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - Business Wire
- 11 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - Business Wire
- 14 days ago - Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 25 days ago - Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - Business Wire
- 6 weeks ago - Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 - Business Wire